MedTrace Logo

A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis

NCT05240300 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2025-08-03

No results posted yet for this study

Summary

The purpose of study BMX-05-001 is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically in adult subjects with moderate to severe atopic dermatitis (AD).

Conditions

Interventions

BIOLOGICAL

BX005-A

phage gel

OTHER

Placebo

vehicle gel

Sponsors & Collaborators

  • Maruho Co., Ltd.

    collaborator INDUSTRY

  • BiomX, Inc.

    lead INDUSTRY

Principal Investigators

  • Urania Rappo, MD · BiomX, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2023-06-30
Completion
2023-06-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05240300 on ClinicalTrials.gov